Results of a phase 3 clinical trial are moving the ball closer to the goal in the field of PSMA PET imaging.
Progress continues in the field of PSMA PET imaging for men with intermediate- or high-risk prostate cancer.
Doctors at UCSF and UCLA report results of a phase 3 clinical trial evaluating the efficacy of 68Ga-PSMA-11 and positron emission tomography (PET) imaging.[i]
Similar to the imaging agent PYLARIFY® used by HALO Diagnostics’ PET technicians, 68Ga-PSMA-11 is an injectable contrasting agent that targets prostate-specific membrane antigen (PSMA), a protein found on the surface of more than 90% of prostate cancer cells.
The study, reported in JAMA Oncology, showed the PET scans had a sensitivity of 40% for detecting the spread of disease into lymph nodes inside and outside the pelvis. The results were confirmed by lymph node biopsy.
The test demonstrated a 95% specificity in detecting which patients in the study did not have nodal metastases.
The PSMA PET scan using 68Ga-PSMA-11 is only available at UCSF and UCLA.
Earlier this year, the National Comprehensive Cancer Network (NCCN) made PYLARIFY (18F-DCFPyl) part of their guidelines on prostate cancer screening and early detection. It is available for use with a HALO Diagnostics PET scan.
If you or a loved one are in need of a prostate cancer diagnostic test, give us a call at 760-469-8057.
Evaluating your options? Seeking a second opinion? Click below to sign up for a complimentary case assessment with a HALO Dx team member:
[i] Hope TA, Eiber M, Armstrong WR, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. Published online September 16, 2021. doi:10.1001/jamaoncol.2021.3771
You should always consult with your doctor(s) when considering treatment options. HALO Dx provides MRI-guided prostate screenings, MRI-guided prostate biopsy, liquid “biopsy” tests, and genomic testing to facilitate informed decisions between doctors and patients. Learn more about HALO Dx's advanced, minimally invasive prostate cancer and BPH treatments including Laser Focal Therapy and TULSA-PRO for whole gland and partial ablations. With the appropriate diagnostic results, our prostate disease experts help you answer any questions you may have about prostate cancer or BPH.